Martin Siu - Aptorum Group Head Finance
| APM Stock | USD 0.65 0.06 8.45% |
Executive
Martin Siu is Head Finance of Aptorum Group Ltd
| Age | 45 |
| Address | 17 Hanover Square, London, United Kingdom, W1S 1BN |
| Phone | 44 20 8092 9299 |
| Web | https://www.aptorumgroup.com |
Aptorum Group Management Efficiency
The company has Return on Asset of (0.323) % which means that on every $100 spent on assets, it lost $0.323. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.374) %, meaning that it generated no profit with money invested by stockholders. Aptorum Group's management efficiency ratios could be used to measure how well Aptorum Group manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.6. At this time, Aptorum Group's Total Assets are very stable compared to the past year. As of the 30th of November 2024, Net Tangible Assets is likely to grow to about 31 M, while Non Current Assets Total are likely to drop about 15 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert Homolka | Neurobo Pharmaceuticals | N/A | |
| Sean Proehl | Dermata Therapeutics | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| Maria MBA | Dermata Therapeutics | 73 | |
| Esther Jhun | Surrozen | N/A | |
| Dolly Tyan | Aditxt Inc | N/A | |
| Sujith MBBS | Biocardia | N/A | |
| MiKyung Kim | Neurobo Pharmaceuticals | N/A | |
| Ralph Cavalli | AIM ImmunoTech | 66 | |
| Covadonga Paneda | Altamira Therapeutics | 50 | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| Edward Gillis | Biocardia | 62 | |
| Christopher McAleer | AIM ImmunoTech | N/A | |
| Doug BA | Dyadic International | N/A | |
| MS MD | Aditxt Inc | N/A | |
| Li Yang | Surrozen | 55 | |
| Pramod Gupta | Unicycive Therapeutics | 64 | |
| Lnaic Teyssdou | Addex Therapeutics | 38 | |
| Ana Rodriguez | Dyadic International | N/A | |
| Bryan Kadotani | Armata Pharmaceuticals | N/A | |
| Pierre Kyme | Armata Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.32 |
Aptorum Group Leadership Team
Elected by the shareholders, the Aptorum Group's board of directors comprises two types of representatives: Aptorum Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptorum. The board's role is to monitor Aptorum Group's management team and ensure that shareholders' interests are well served. Aptorum Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptorum Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wai Lee, Head RD | ||
| Martin Siu, Head Finance | ||
| Darren Lui, Chief CEO | ||
| Kwok Wong, Head Finance | ||
| Chung Huen, Founder Director | ||
| Clark Cheng, Chief Director |
Aptorum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptorum Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (24.86) % | ||||
| Current Valuation | 5.24 M | ||||
| Shares Outstanding | 3.81 M | ||||
| Shares Owned By Insiders | 23.71 % | ||||
| Shares Owned By Institutions | 1.45 % | ||||
| Number Of Shares Shorted | 13.12 K | ||||
| Price To Earning | 2.70 X | ||||
| Price To Book | 0.16 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptorum Group Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptorum Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.095 | Quarterly Revenue Growth (1.00) | Return On Assets (0.32) | Return On Equity (0.37) |
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptorum Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptorum Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptorum Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.